Registration Open!
ACT proudly introduces a new course, Biologics Nonclinical Drug Development. This course delves into regulatory considerations and toxicologic evaluation of protein biologics, cell and gene therapies, and oncolytic viruses. Participants will explore key principles and methodologies in nonclinical safety assessment, covering studies from candidate selection to marketing authorization, including toxicity, safety pharmacology, and immunogenicity. Case studies will illustrate strategies and issues unique to these advanced therapeutic modalities.